iodixanol (visipaque) Report issue

Small molecule Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem

Active Ingredient History

NOW
  • Now
Iodixanol (brand name VISIPAQUE) is an iodine-containing nonionic dimeric hydrophilic contrast agent for intravascular (intravenous and intra-arterial) use during coronary angiography. Pharmacodynamics studies indicated that iodixanol had fewer cardiovascular effects, caused less renal damage and were associated with similar or smaller changes to the blood-brain barrier and neurological function when compared with nonionic contrast media. It is known, that the organic iodine compounds attenuate x-rays as they pass through the body, thereby allowing the body structures containing iodine to be delineated in contrast to those structures that do not contain iodine. The degree of opacity produced by these compounds is directly proportional to the total amount (concentration and volume) of the iodinated contrast agent in the path of the x-rays. Thus, after intravascular administration, iodixanol makes opaque those internal structures in its path of flow, allowing their visualization until significant hemodilution and elimination occur.   NCATS

Chemistry

  • SMILES: CC(=O)N(CC(O)CN(C(C)=O)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I)C2=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C2I
  • InChIKey: NBQNWMBBSKPBAY-UHFFFAOYSA-N
  • Mol. Mass: 1550.1819
  • ALogP: Missing data
  • ChEMBL Molecule:
    iodixanol  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Parenteral
  • Pro Drug: No

Drug Pricing (per unit)

United States

$15.2110 - $141.7360
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

1,3-benzenedicarboxamide, 5,5'-((2-hydroxy-1,3-propanediyl)bis(acetylimino))bis(n,n'-bis(2,3-dihydroxypropyl)-2,4,6-triiodo)-, (16alpha)- | 2-541o-3a | 5,5'-((2-hydroxytrimethylene)bis(acetylimino))bis(n,n'-bis(2,3-dihydroxypropyl)-2,4,6-triiodoisophthalamide) | contrast media 2-5410-3 | indixanol | iodixanol | iodixanol-320 | iodixanolum | nasapaque | pegylated liposomal iodixanol | visiopaque | visipaque | visipaque | visipaque 270 | visipaque 320 | visipaque unique softpac

Organizations (40)

Research & Development (39)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (2)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (27)

Approved Indications (1)


 

Cardiovascular Diseases (approved 1996)

Experimental Indications - Clinical Trial Phases 1-4 (26)


 

Angioplasty, Balloon, Coronary (Phase 4)

Arterial Occlusive Diseases (Phase 4)

Atherosclerosis (Phase 3)

Back Pain (Phase 4)

Carotid Stenosis (Phase 3)

Contrast Media (Phase 4)

Coronary Angiography (Phase 4)

Coronary Artery Disease (Phase 4)

Coronary Disease (Phase 3)

Coronary Stenosis (Phase 4)

Diabetes Mellitus (Phase 4)

Diagnostic Imaging (Phase 4)

Head and Neck Neoplasms (Phase 1)

Healthy Volunteers (Phase 1/Phase 2)

Hypothyroidism (Phase 4)

Ischemic Stroke (Phase 3)

Kidney Diseases (Phase 4)

Kidney Failure, Chronic (Phase 4)

Lung Neoplasms (Phase 4)

Myocardial Infarction (Phase 4)

Pharmacological and Toxicological Phenomena (Phase 4)

Pulmonary Embolism (Phase 4)

Renal Artery Obstruction (Phase 4)

Renal Insufficiency (Phase 4)

Renal Insufficiency, Chronic (Phase 4)

Rhinitis, Allergic, Seasonal (Phase 1/Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 42
  • # of Trial Organizations: 39

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue